新诊断多发性骨髓瘤自体干细胞移植趋势:1995至2019年欧洲血液与骨髓移植学会中心的人口学与结局变化
该回顾性分析纳入1995至2019年欧洲血液与骨髓移植学会575个中心共117 711例首次接受自体干细胞移植的新诊断多发性骨髓瘤患者,移植数量增加七倍,中位年龄从55岁升至61岁,>65岁患者比例从7%升至30%,硼替佐米方案基本取代化疗诱导,2年完全缓解率从22%升至42%,5年无进展生存率和总生存率分别从28%升至31%、从52%升至69%,移植死亡率从5.9%降至1.5%。
要点
- 移植数量增加七倍,中位年龄从55岁升至61岁,>65岁患者比例从7%升至30%。
- 化疗诱导显著减少,基本被硼替佐米方案取代,2年完全缓解率从22%升至42%。
- 5年无进展生存率从28%升至31%,5年总生存率从52%升至69%,移植死亡率从5.9%降至1.5%。
核心结论
- 多发性骨髓瘤治疗的持续进展可能挑战自体干细胞移植的未来角色,但在当前时期自体干细胞移植仍是多发性骨髓瘤治疗范式的核心。
研究设计与样本
- 对1995至2019年在欧洲血液与骨髓移植学会中心首次接受自体干细胞移植的多发性骨髓瘤患者进行回顾性分析,共纳入575个中心的117 711例患者。
主要发现
- 研究期间移植数量增加七倍,中位年龄从55岁升至61岁,>65岁患者比例从7%升至30%。
- 化疗诱导使用显著下降,基本被硼替佐米方案取代。
- 2年完全缓解率从22%升至42%。
- 5年无进展生存率从28%升至31%,5年总生存率从52%升至69%。
- 移植死亡率从5.9%降至1.5%。
临床怎么用
- 原文结论指出,多发性骨髓瘤治疗的持续进展可能挑战自体干细胞移植的未来角色,但在当前时期自体干细胞移植仍是多发性骨髓瘤治疗范式的核心。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) accounts for 10% of haematological malignancies. Overall survival (OS) has improved in recent years due to increased use of autologous stem cell transplantation (ASCT) in the treatment of newly diagnosed MM and the advent of novel agents, including proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies. To assess trends in ASCT including patient selection, choice of induction regimen, depth of response and survival, we performed a retrospective analysis of all patients undergoing first ASCT for MM in European Society for Blood and Marrow Transplantation centres between 1995 and 2019. A total of 117 711 patients across 575 centres were included. The number of transplants performed increased sevenfold across the study period. The median age increased from 55 to 61 years, and the percentage of patients aged >65 years rose from 7% to 30%. Use of chemotherapy-based induction fell significantly, being largely replaced by bortezomib-based regimens. The two-year complete response rate increased from 22% to 42%. The five-year progression-free survival and OS rates increased from 28% to 31% and from 52% to 69%, respectively. Transplant mortality fell from 5.9% to 1.5%. Ongoing advances in MM treatment may challenge the future role of ASCT. However, at the current time, ASCT remains central to the MM treatment paradigm.
引用
- Swan D, Hayden PJ, Eikema DJ, et al. Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019. Br J Haematol. 2022. PMID: 35166376. doi:10.1111/bjh.18025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。